Abstract: Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ?20 ?m to ?500 ?mm uses and kits therefor.

Abstract: A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.

Abstract: A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.

Abstract: An Exhaled Breath Temperature (EBT) monitor for the measurement of portions of exhaled respiratory gas temperature during a single exhalation, the monitor comprising: An inlet channel for receiving a stream of exhaled respiratory gas, a plurality of measurement chambers, temperature sensors located within more than one measurement chamber adapted for measuring the temperature of exhaled respiratory gas, a plurality of valves intermediate the air channel and each measurement chamber, configured to selectively pass portions of the gas stream in to each chamber and a control unit, configured to operate the valves and record the measurements of the temperature sensor

Abstract: A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.

Abstract: An aqueous pharmaceutical composition comprising: a) 0.005 to 10% by wt of one or more water-soluble pharmaceutically active ingredients or pharmaceutically acceptable salts thereof; b) from 0.01 to 10% by wt hydroxypropyl methyl cellulose having a viscosity of from 2500 to 5500 cps (mPa·s); and c) a buffer for maintaining the pH of the aqueous pharmaceutical composition from 5 to 7; can be prepared by a method which comprises: i) dissolving the above components in water to form an aqueous solution, and ii) filtering the aqueous solution formed in i) through a sieve having a mesh size from ?1 micron but ?10 microns. The compositions obtainable by this method are capable of demonstrating improved mucoadhesive consistency and stability.